Skip to content

梯瓦制药

US · TEVA #471 按市值排名 上市于 1970
41.50 +0.39 +0.95%
实时 - 追踪5344个代码 - 心跳于520秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

增持
  • 最近一期（2026/Q3）披露持股的机构数量减少了9家。
  • 机构持股总比例上升了3.2个百分点。

机构持股

机构持股比例
80.86% +3.24pp
机构数量
837 -9
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund57.99%
Public Company6.49%
Sovereign Wealth Fund6.06%
Hedge Fund4.55%
Government Pension Fund2.03%
Family Office/Trust1.85%
Private Company1.44%
Individual/Insider0.43%
Insurance Company0.18%
Other18.99%

主要股东 截至 2026-09-30

BlackRock 8.36% · 97.44M 股
Norges Bank Investment Management 6.01% · 70.08M 股
Phoenix Investments & Finances Ltd 5.35% · 62.32M 股
Harel Insurance Investments & Financial Services Ltd 4.18% · 48.76M 股
WCM Investment Management 3.71% · 43.25M 股
Vanguard Capital Management, LLC 3.68% · 42.87M 股
Clal Financial Management Ltd 3.48% · 40.60M 股
Migdal Mutual Funds Ltd. 3.46% · 40.37M 股
Menora Mivtachim Provident Funds 3.42% · 39.85M 股
FMR 2.31% · 26.90M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 26次买入 · 24次卖出

姓名职务持股比例
Amir Elstein Independent Director 0.18%
Richard Francis Chief Executive Officer 0.10%
Sol Barer Independent Chairperson 0.04%
Eric Hughes Executive VP of Global R&D and Chief Medical Officer 0.01%
Gerald Lieberman Independent Director 0.01%
Rosemary Crane Independent Director 0.01%
Roberto Mignone Independent Director 0.01%
Perry Nisen Independent Director 0.01%
Ronit Satchi-Fainaro Independent Director 0.01%
Mark Sabag Executive Vice President of International Markets Commercial 0.01%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-17 Bridger Management LLC -- Intent to Sell (Form 144) -367,600 $39.19
2026-09-17 Brian Savage Interim Chief Legal Officer Open Market Disposition -2,839 $38.70–39.15
2026-09-17 Brian Savage Interim Chief Legal Officer Derivative Exercise and Sale -4,503 $34.70–38.69
2026-08-20 Ronit Satchi-Fainaro Independent Director Private Disposition -415 $37.25
2026-08-20 Amir Weiss Chief Accounting Officer Private Disposition -6,945 $37.61
2026-08-20 Amir Weiss Chief Accounting Officer Derivative Exercise and Sale -2,500 $19.61–37.63
2026-08-16 Evan Lippman Executive Vice President, Business Development Automatic Disposition -18,600 $36.57
2026-08-04 Tal Zaks Independent Director Private Disposition -17 $34.87
2026-08-02 Eric Hughes Executive VP of Global R&D and Chief Medical Officer Derivative Exercise and Sale -25,578 $34.88
2026-08-02 Eric Hughes Executive VP of Global R&D and Chief Medical Officer Derivative Exercise and Retained +27,166 --
2026-08-02 Placid Jover Executive VP & CHRO Derivative Exercise and Sale -12,827 $34.88
2026-06-17 Matthew Shields Officer Private Disposition -9,989 $32.19
2026-06-10 Eliyahu Kalif Chief Financial Officer Automatic Disposition -106,563 $34.10
2026-06-04 Sol Barer Independent Chairperson Derivative Exercise and Retained +21,739 --
2026-06-04 Amir Elstein Independent Director Derivative Exercise and Retained +14,492 --
2026-06-04 Gerald Lieberman Independent Director Derivative Exercise and Retained +14,492 --
2026-06-04 Roberto Mignone Independent Director Derivative Exercise and Retained +14,492 --
2026-06-04 Rosemary Crane Independent Director Derivative Exercise and Retained +14,492 --
2026-06-04 Richard Francis Chief Executive Officer Derivative Exercise and Sale -6,153 $34.35
2026-06-04 Richard Francis Chief Executive Officer Derivative Exercise and Retained +6,890 --

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:31 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

梯瓦制药 讨论区 0 条评论

发表评论